DataWorks
B2B Marketing Data, Attribution & Analytics
Without visibility, you're flying blind. Without correlation, you're guessing.
Most marketing teams are rich in dashboards and poor in answers. DataWorks covers attribution, measurement infrastructure, and the intelligence layer that makes every other marketing investment legible.
Without visibility you are flying blind; without correlation you are guessing — this section is about replacing both with evidence.
LinkedIn Ads Conversion Tracking: Insight Tag, CAPI, and the B2B Attribution Gap
Your LinkedIn Campaign Manager shows 300 demo requests while your CRM shows 14 opportunities, and neither number tells the whole story. Here's why the B2B attribution gap isn't a technical problem, it's structural, and what you can actually do about it.
The Post-Cookie Stack Audit Your CFO Will Actually Read
Forty percent of your attribution data isn't at risk, it's already gone. Here's the three-pillar architecture that separates the organizations building structural advantage from those waiting for an ecosystem that will never stabilize.
Martech at a Crossroads: Privacy-First Identity, Measurement & Orchestration
Your CAC payback period is quietly determining whether you're winning or losing, and the martech stack you build in the next 12 months will decide which side you land on. Here's the privacy-first blueprint that survives both signal loss and CFO scrutiny.
Accurate ROI Tracking For Ads: A Complete Guide
Ask any CMO which campaigns drove closed-won revenue last quarter, and watch the room go quiet. The gap between ad activity and ad ROI doesn't close itself, but the teams building proper measurement infrastructure are finally proving marketing's worth in the language finance speaks.
When "Deidentified" Becomes the Compliance Bet of the Decade
Healthcare marketers are betting big on "deidentified" patient data for precision targeting, but the compliance math is getting uncomfortable. When fertility clinic audiences and medical tourism segments rely on narrow patient cohorts, the line between compliant targeting and regulatory risk becomes razor-thin.